Lacutamab Advances Toward Phase 3 Trial in T-Cell Lymphoma
Sobi and Innate Pharma partner to advance lacutamab into a Phase 3…
Strategic Research Partnership Expands Patient Access to Clinical Trials
A new strategic research partnership aims to expand patient access to clinical…
Major Acquisition to Advance Therapies for Treatment-Resistant Depression
Lilly will acquire AtaiBeckley in a deal valued at up to $3.8…
Global Oncology Pipeline Set to Expand With Next-Generation Cancer Drug Innovation
Novartis will acquire UK-based Myricx Bio in a deal worth up to…
WHO Releases First-Ever Guidance to Advance Child-Focused Dengue Treatments
WHO has released its first-ever guidance to accelerate the development of child-focused…
KFSH Space Medicine Study Ranks Among Top 5% Globally on Altmetric
A KFSH-led study conducted aboard the International Space Station has ranked among…
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi has announced the discontinuation of its Phase 3 MOBILIZE study evaluating…
FDA approves Lilly’s EBGLYSS® for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
The U.S. FDA has approved a new maintenance dosing regimen for Eli…
Harbour BioMed Announces NMPA Acceptance for the Treatment of Advanced Solid Tumors
Harbour BioMed has announced that China’s National Medical Products Administration (NMPA) has…
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory to Expand BCG Supply in the United States
ImmunityBio has signed an exclusive U.S. development and supply agreement with Japan…
